BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

932 related articles for article (PubMed ID: 23963659)

  • 21. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.
    Chen SM; Liu JL; Wang X; Liang C; Ding J; Meng LH
    Biochem Pharmacol; 2012 May; 83(9):1183-94. PubMed ID: 22305748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sorafenib inhibits liver cancer growth by decreasing mTOR, AKT, and PI3K expression.
    Zhang CZ; Wang XD; Wang HW; Cai Y; Chao LQ
    J BUON; 2015; 20(1):218-22. PubMed ID: 25778319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphorylation-independent mTORC1 inhibition by the autophagy inducer Rottlerin.
    Torricelli C; Daveri E; Salvadori S; Valacchi G; Ietta F; Muscettola M; Carlucci F; Maioli E
    Cancer Lett; 2015 Apr; 360(1):17-27. PubMed ID: 25661734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
    Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
    PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
    Yokoi K; Kobayashi A; Motoyama H; Kitazawa M; Shimizu A; Notake T; Yokoyama T; Matsumura T; Takeoka M; Miyagawa SI
    Oncol Rep; 2018 Feb; 39(2):843-850. PubMed ID: 29251327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK.
    Zhou H; Shang C; Wang M; Shen T; Kong L; Yu C; Ye Z; Luo Y; Liu L; Li Y; Huang S
    Biochem Pharmacol; 2016 Sep; 116():39-50. PubMed ID: 27396756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. mTORC1-Dependent Metabolic Reprogramming Underlies Escape from Glycolysis Addiction in Cancer Cells.
    Pusapati RV; Daemen A; Wilson C; Sandoval W; Gao M; Haley B; Baudy AR; Hatzivassiliou G; Evangelista M; Settleman J
    Cancer Cell; 2016 Apr; 29(4):548-562. PubMed ID: 27052953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cucurbitacin E Induces Autophagy via Downregulating mTORC1 Signaling and Upregulating AMPK Activity.
    Zha QB; Zhang XY; Lin QR; Xu LH; Zhao GX; Pan H; Zhou D; Ouyang DY; Liu ZH; He XH
    PLoS One; 2015; 10(5):e0124355. PubMed ID: 25970614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
    Locatelli SL; Giacomini A; Guidetti A; Cleris L; Mortarini R; Anichini A; Gianni AM; Carlo-Stella C
    Leukemia; 2013 Aug; 27(8):1677-87. PubMed ID: 23360848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells.
    Woo YM; Shin Y; Lee EJ; Lee S; Jeong SH; Kong HK; Park EY; Kim HK; Han J; Chang M; Park JH
    PLoS One; 2015; 10(7):e0132285. PubMed ID: 26158266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogen-induced activation of mammalian target of rapamycin is mediated via tuberin and the small GTPase Ras homologue enriched in brain.
    Yu J; Henske EP
    Cancer Res; 2006 Oct; 66(19):9461-6. PubMed ID: 17018601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
    Xargay-Torrent S; López-Guerra M; Montraveta A; Saborit-Villarroya I; Rosich L; Navarro A; Pérez-Galán P; Roué G; Campo E; Colomer D
    Clin Cancer Res; 2013 Feb; 19(3):586-97. PubMed ID: 23231952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic activity of letrozole and sorafenib on breast cancer cells.
    Bonelli MA; Fumarola C; Alfieri RR; La Monica S; Cavazzoni A; Galetti M; Gatti R; Belletti S; Harris AL; Fox SB; Evans DB; Dowsett M; Martin LA; Bottini A; Generali D; Petronini PG
    Breast Cancer Res Treat; 2010 Nov; 124(1):79-88. PubMed ID: 20054642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
    Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
    Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2-Deoxy-D-glucose cooperates with arsenic trioxide to induce apoptosis in leukemia cells: involvement of IGF-1R-regulated Akt/mTOR, MEK/ERK and LKB-1/AMPK signaling pathways.
    Estañ MC; Calviño E; de Blas E; Boyano-Adánez Mdel C; Mena ML; Gómez-Gómez M; Rial E; Aller P
    Biochem Pharmacol; 2012 Dec; 84(12):1604-16. PubMed ID: 23041229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Docosahexaenoic acid attenuates breast cancer cell metabolism and the Warburg phenotype by targeting bioenergetic function.
    Mouradian M; Kikawa KD; Dranka BP; Komas SM; Kalyanaraman B; Pardini RS
    Mol Carcinog; 2015 Sep; 54(9):810-20. PubMed ID: 24729481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation.
    Honma Y; Harada M
    Exp Cell Res; 2013 Aug; 319(14):2166-78. PubMed ID: 23727131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stimulatory effects of sorafenib on human non‑small cell lung cancer cells in vitro by regulating MAPK/ERK activation.
    Zhang YN; Wu XY; Zhong N; Deng J; Zhang L; Chen W; Li X; Zhong CJ
    Mol Med Rep; 2014 Jan; 9(1):365-9. PubMed ID: 24213303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Energy depletion of bovine mammary epithelial cells activates AMPK and suppresses protein synthesis through inhibition of mTORC1 signaling.
    Burgos SA; Kim JJ; Dai M; Cant JP
    Horm Metab Res; 2013 Mar; 45(3):183-9. PubMed ID: 22972179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.
    Groenendijk FH; Mellema WW; van der Burg E; Schut E; Hauptmann M; Horlings HM; Willems SM; van den Heuvel MM; Jonkers J; Smit EF; Bernards R
    Int J Cancer; 2015 Mar; 136(6):1434-44. PubMed ID: 25080865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.